Clinical trials: Insulin, completed
Gestational Diabetes
Maternal Weight Gain in Gestational Diabetes Controlled by Metformin Versus Insulin
Insulin has many disadvantages for mothers with GDM including the need to give injections, frequent daily testing for monitoring, and risks of hypoglycemia, increase in appetite, weight gain and high cost.
- Trial name
- NCT03841591
- Testing
- Insulin, Metformin, Assessment of weight gain
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Type 1 Diabetes
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
Regular physical activity is associated with many health benefits for individuals with type 1 diabetes including improved cardiovascular fitness and vascular health, decreased insulin requirements, improved body composition and…
- Trial name
- NCT02855307
- Testing
- 60-minute exercise, Insulin pump, Dexcom G4 Platinum glucose sensor
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Institut de Recherches Cliniques de Montreal
Diabetes, Diabetes Mellitus, Type 2
A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients
This trial is conducted globally. The aim of this trial is to compare stepwise insulin intensification of biphasic insulin aspart (BIAsp) 30 and basal-bolus therapy with insulin glargine and insulin aspart in insulin naïve type 2…
- Trial name
- NCT02453685
- Testing
- biphasic insulin aspart 30, insulin glargine, insulin aspart
- Where
- 41 sites in Australia, Bulgaria and 7 more
- Volunteers
- 335 people
- Sponsor
- Novo Nordisk A/S
Closed Loop, Diabetes Mellitus, Type 1
Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7)
The study will be conducted in crossover trial, with two 12-weeks periods separated by a Wash-out period of at least one month. According to randomization ,patients will be provided with either Diabeloop system or the usual…
- Trial name
- WP7 (NCT02987556)
- Testing
- Continuous Glucose Monitoring, External Insulin Pump, telemdecine
- Where
- 12 sites in France
- Volunteers
- 71 people
- Sponsor
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Type 1 Diabetes Mellitus
A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
The goal of this study is to determine if Hylenex recombinant leads to changes in the insulin time-action profiles and glucose responses when preadministered in the setting of continuous subcutaneous insulin infusion (CSII)…
- Trial name
- HALO-117-406 (NCT03662334)
- Testing
- Rapid Acting insulin with pre-treatment of rHuPH20
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
The study aims to evaluate arterial stiffness and endothelial function indexes and their relationship with clinic and laboratory varible in a group of diabetic patients in treatment with dulaglutide
- Trial name
- NCT03824002
- Testing
- Dulaglutide, Aspart insulin, Glargine
- Where
- Italy
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare FIAsp (faster-acting insulin aspart) to insulin aspart, both in combination with insulin glargine and metformin in adults with type 2…
- Trial name
- onset® 2 (NCT01819129)
- Testing
- Faster-acting insulin aspart, Insulin aspart, Insulin glargine
- Where
- 144 sites in United States, Canada and 8 more
- Volunteers
- 881 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Insulin Resistance, Glucose Intolerance
Endothelial Function in Obese Adolescents
Childhood obesity is perhaps the most significant public health problem in the most developed countries and is rapidly becoming so in developing countries.
- Conditions
- Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
- Trial name
- NCT01879033
- Testing
- Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Liver Transplant
Intraoperative Glucose Control in Liver Transplant
The goal of the proposed study is to evaluate the effectiveness of intraoperative, strict glycemic control to improve survival and infection rates following liver transplantation in a randomized, prospective trial.Primary…
- Trial name
- NCT00780026
- Testing
- insulin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan
Diabetes Mellitus (DM)
Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM
Purpose: To compare efficacy and safety of traditional sliding scale insulin (SSI) versus modified 70/30 insulin versus modified basal plus supplemental scale /bolus insulin regimens for glycemic control in hospitalized diabetic…
- Trial name
- NCT01855243
- Testing
- regular insulin, 70/30 insulin, Glargine
- Where
- Egypt
- Volunteers
- 63 people
- Sponsor
- Cairo University
Type 1 Diabetes Mellitus
A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)
The purpose of Part I of this study is to evaluate the safety and tolerability of intravenous (IV) doses of MK-2640 in healthy participants and to obtain preliminary plasma pharmacokinetic profiles of MK-2640.
- Trial name
- NCT02269735
- Testing
- MK-2640, Regular Human Insulin (RHI), Dextrose
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes, Hypoglycemia
Insulin Management for Exercise in Patients With Type 1 Diabetes
The purpose of this study is to compare the time spent in glucose target range (4.0-10.0 mmol/L) during exercise and in recovery using three different basal insulin management strategies for prolonged aerobic exercise: A) pump…
- Conditions
- Type 1 Diabetes, Hypoglycemia, Physical Activity
- Trial name
- NCT03130101
- Testing
- Change in their basal insulin rate
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- York University
Type 2 Diabetes Mellitus
A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey
Primary Objective: To assess the mean change in HbA1c (glycated haemoglobin). Secondary Objectives: To evaluate the efficacy and safety of the titration of insulin glargine U300 in terms of: Targeted HbA1c; Targeted fasting self…
- Trial name
- EASE (NCT02954692)
- Testing
- INSULIN GLARGINE (U300), metformin, sulfonylurea
- Where
- Turkey (Türkiye)
- Volunteers
- 112 people
- Sponsor
- Sanofi
Obesity
Pupillography as Screening Tool for Brain Insulin Resistance
Cerebral insulin action is important in the regulation of whole body glucose metabolism. However, the cerebral insulin action differs between individuals - there is a so called cerebral insulin resistance.
- Trial name
- NCT03651661
- Testing
- human insulin, Pupillography
- Where
- Germany
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with…
- Trial name
- DUAL™ II (NCT01392573)
- Testing
- insulin degludec/liraglutide, insulin degludec
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 413 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes…
- Trial name
- DUAL™ III (NCT01676116)
- Testing
- insulin degludec/liraglutide, liraglutide, exenatide
- Where
- 109 sites in United States, Australia and 3 more
- Volunteers
- 438 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ V (NCT01952145)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 91 sites in United States, Argentina and 8 more
- Volunteers
- 557 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to compare the safety and efficacy of insulin degludec (IDeg) and insulin glargine (IGlar), both with insulin aspart (IAsp) as…
- Trial name
- SWITCH 1 (NCT02034513)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 99 sites in United States, Poland and 1 more
- Volunteers
- 501 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with biphasic insulin aspart (BIAsp) 30 in patients with type 2 diabetes not optimally controlled on…
- Trial name
- BOOST™ (NCT01059812)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 46 sites in Hong Kong, Japan and 3 more
- Volunteers
- 424 people
- Sponsor
- Novo Nordisk A/S